• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于人类白血病的反义寡核苷酸疗法。

Antisense oligonucleotide therapeutics for human leukemia.

作者信息

Gewirtz A M

机构信息

University of Pennsylvania School of Medicine, Philadelphia 19104, USA.

出版信息

Curr Opin Hematol. 1998 Jan;5(1):59-71. doi: 10.1097/00062752-199801000-00011.

DOI:10.1097/00062752-199801000-00011
PMID:9515205
Abstract

The development of reliable gene disruption strategies, and their application in living cells, has proven to be an extraordinary important advance for cell and molecular biologists. Using the various available approaches, the specific functions of any given gene may now be investigated directly in the relevant cell type. Application of similar experimental tools in a clinical setting might prove to be equally valuable and could well form the basis of a monumental advance in the practice of clinical medicine. This seems particularly true at the present time because much progress has been made in understanding the molecular pathogenesis of many diseases, including cancer. For these reasons a tremendous amount of interest has been generated in the use of oligodeoxynucleotides to modify gene expression. However, in spite of some notable successes which are detailed in this review, oligonucleotides have generated controversy in regard to their mechanism of action, reliability, and ultimate therapeutic utility. Nevertheless, the potential power of the "antisense" approach remains undisputed, and its ultimate therapeutic utility is far reaching. Accordingly, the problems associated with the use of these compounds are clearly worth solving. It remains the hope of many laboratories that the day will soon come when these techniques will make an important contribution to the management of chronic myelogenous leukemia and other neoplastic disorders.

摘要

可靠的基因破坏策略的发展及其在活细胞中的应用,已被证明是细胞和分子生物学家取得的一项极其重要的进展。利用各种现有方法,现在可以直接在相关细胞类型中研究任何给定基因的特定功能。在临床环境中应用类似的实验工具可能同样有价值,并且很可能成为临床医学实践中一项重大进展的基础。目前尤其如此,因为在理解包括癌症在内的许多疾病的分子发病机制方面已经取得了很大进展。出于这些原因,人们对使用寡脱氧核苷酸来改变基因表达产生了极大的兴趣。然而,尽管本综述详细介绍了一些显著的成功案例,但寡核苷酸在其作用机制、可靠性和最终治疗效用方面仍存在争议。尽管如此,“反义”方法的潜在力量仍然无可争议,其最终治疗效用影响深远。因此,与使用这些化合物相关的问题显然值得解决。许多实验室仍然希望,这些技术对慢性粒细胞白血病和其他肿瘤性疾病的治疗做出重要贡献的那一天很快就会到来。

相似文献

1
Antisense oligonucleotide therapeutics for human leukemia.用于人类白血病的反义寡核苷酸疗法。
Curr Opin Hematol. 1998 Jan;5(1):59-71. doi: 10.1097/00062752-199801000-00011.
2
Antisense oligonucleotide therapeutics for human leukemia.用于人类白血病的反义寡核苷酸疗法。
Crit Rev Oncog. 1997;8(1):93-109. doi: 10.1615/critrevoncog.v8.i1.50.
3
BCR-ABL: an anti-apoptosis gene in chronic myelogenous leukemia.BCR-ABL:慢性髓性白血病中的一种抗凋亡基因。
Leuk Lymphoma. 1995 Jul;18(3-4):231-6. doi: 10.3109/10428199509059612.
4
Oligonucleotide therapeutics for human leukaemia.用于人类白血病的寡核苷酸疗法。
Ciba Found Symp. 1997;209:169-91; discussion 191-4.
5
Ribonuclease H-mediated antisense effects in intact human leukaemia cells.
Biochem Soc Trans. 1996 Aug;24(3):619-23. doi: 10.1042/bst0240619.
6
Treatment of chronic myelogenous leukemia (CML) with c-myb antisense oligodeoxynucleotides.用c-myb反义寡脱氧核苷酸治疗慢性粒细胞白血病(CML)。
Bone Marrow Transplant. 1994;14 Suppl 3:S57-61.
7
Chronic myeloid leukaemia--the XXI century.慢性髓细胞白血病——21世纪
Leuk Lymphoma. 1993;11 Suppl 1:7-9. doi: 10.3109/10428199309047855.
8
Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems.
Leukemia. 2000 Mar;14(3):347-55. doi: 10.1038/sj.leu.2401677.
9
Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.环磷酰胺与bcr/abl反义寡脱氧核苷酸联合治疗重症联合免疫缺陷小鼠的费城白血病
J Natl Cancer Inst. 1997 Jan 15;89(2):124-33. doi: 10.1093/jnci/89.2.124.
10
Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.BCR-ABL反义寡脱氧核苷酸对慢性髓性白血病细胞生长的基因靶向特异性抑制作用。
Folia Histochem Cytobiol. 1991;29(3):85-9.

引用本文的文献

1
Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.GTI-2040(一种核糖核苷酸还原酶反义药物)与大剂量阿糖胞苷联合用于复发/难治性急性髓细胞白血病患者的I期研究。
Leuk Lymphoma. 2014 Jun;55(6):1332-6. doi: 10.3109/10428194.2013.838764. Epub 2013 Nov 1.
2
Efficient silencing of gene expression by an ASON-bulge-DNAzyme complex.通过 ASON-凸起-DNA 酶复合物实现基因表达的高效沉默。
PLoS One. 2011 Apr 7;6(4):e18629. doi: 10.1371/journal.pone.0018629.
3
Delivery of antisense oligodeoxyribonucleotide lipopolyplex nanoparticles assembled by microfluidic hydrodynamic focusing.
通过微流体力聚焦组装的反义寡脱氧核苷酸脂质多聚物纳米粒的递呈。
J Control Release. 2010 Jan 4;141(1):62-9. doi: 10.1016/j.jconrel.2009.08.019. Epub 2009 Aug 28.
4
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.一项关于GTI-2040(一种核糖核苷酸还原酶反义药物)联合大剂量阿糖胞苷治疗急性髓系白血病患者的I期研究。
Clin Cancer Res. 2008 Jun 15;14(12):3889-95. doi: 10.1158/1078-0432.CCR-08-0109.
5
Click chemistry, a powerful tool for pharmaceutical sciences.点击化学,一种用于制药科学的强大工具。
Pharm Res. 2008 Oct;25(10):2216-30. doi: 10.1007/s11095-008-9616-1. Epub 2008 May 29.